Adding New Treatments for Newly Diagnosed Follicular Lymphoma Patients

Recruiting · Phase 2 · Follicular Lymphoma and related conditions · District of Columbia, New Jersey and New York

Check if I qualify View on ClinicalTrials.gov

About this trial

This study is looking at how well mosunetuzumab works for people with follicular lymphoma that has just been diagnosed. The goal is to learn if this treatment is effective for patients who have not yet received any treatment for their disease. After the first 53 participants, the study will include 23 more participants to gather more information.

This is a Phase 2 trial, which means it is looking at how well the treatment works and how safe it is. The trial is regulated by the FDA and hopes to include about 152 participants.

Who can join

The study is open to adults aged 18 and older, both men and women. Participants need to have newly diagnosed follicular lymphoma and need systemic therapy. The trial team will confirm eligibility before anyone can join.

Conditions

Follicular Lymphoma, Lymphoma

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will receive one of two treatments: either mosunetuzumab alone or mosunetuzumab combined with zanubrutinib. Everyone in the study will receive treatment, but they will not be randomly assigned to a group. The treatments will be given over several cycles, with specific doses scheduled on certain days.